(Q34377145)

1 August 2017

title

Myasthenia gravis: an update for the clinician (English)

1 reference

1 August 2017

0 references

J P Sieb

1

1 reference

1 August 2017

publication date

1 March 2014

1 reference

Clinical and Experimental Immunology

1 August 2017

published in

1 reference

1 August 2017

volume

175

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

408-418

1 reference

Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada

1 August 2017

cites work

1 reference

Change in myasthenia gravis epidemiology in Trento, Italy, after twenty years.

21 January 2018

1 reference

Characteristics of late-onset myasthenia gravis

21 January 2018

1 reference

IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis

21 January 2018

1 reference

To build a synapse: signaling pathways in neuromuscular junction assembly

21 January 2018

1 reference

Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies

21 January 2018

1 reference

Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis

21 January 2018

1 reference

Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis.

21 January 2018

1 reference

MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis

21 January 2018

1 reference

Complete stable remission and autoantibody specificity in myasthenia gravis

21 January 2018

1 reference

Severe neonatal myasthenia due to maternal anti-MuSK antibodies.

21 January 2018

1 reference

Anti-MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamine.

21 January 2018

1 reference

Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction

21 January 2018

1 reference

Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction

21 January 2018

1 reference

Anti-MuSK autoantibodies block binding of collagen Q to MuSK.

21 January 2018

1 reference

Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts

21 January 2018

1 reference

Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience

21 January 2018

1 reference

Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1.

21 January 2018

1 reference

Thymus changes in anti-MuSK-positive and -negative myasthenia gravis

21 January 2018

1 reference

Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG.

21 January 2018

1 reference

Long-lasting treatment effect of rituximab in MuSK myasthenia.

21 January 2018

1 reference

Multidisciplinary treatment of malignant thymoma

21 January 2018

1 reference

Thymoma and thymic carcinoma.

21 January 2018

1 reference

Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients

21 January 2018

1 reference

Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature.

21 January 2018

1 reference

Neuromyelitis Optica in Patients With Myasthenia Gravis Who Underwent Thymectomy

21 January 2018

1 reference

Herzmyasthenie: myasthenia of the heart.

21 January 2018

1 reference

Autoimmune targets of heart and skeletal muscles in myasthenia gravis

21 January 2018

1 reference

Myasthenia gravis: sleep quality, quality of life, and disease severity

21 January 2018

1 reference

Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis

21 January 2018

1 reference

Thymectomy for nonthymomatous myasthenia gravis: a critical analysis

21 January 2018

1 reference

Comparison of open and minimally invasive thymectomies at a single institution.

21 January 2018

1 reference

Thymectomy for non-thymomatous myasthenia gravis: a comparison of surgical methods and analysis of prognostic factors

21 January 2018

1 reference

Status of the thymectomy trial for nonthymomatous myasthenia gravis patients receiving prednisone

21 January 2018

1 reference

Treatment of myasthenia gravis: focus on pyridostigmine.

21 January 2018

1 reference

Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: Results of a prospective multicenter open-label trial

21 January 2018

1 reference

Antisense treatment for myasthenia gravis: experience with monarsen

21 January 2018

1 reference

Long-term treatment of refractory myasthenia gravis with immunoadsorption

21 January 2018

1 reference

Myasthenic crisis: guidelines for prevention and treatment

21 January 2018

1 reference

A retrospective study of complications of therapeutic plasma exchange in myasthenia

21 January 2018

1 reference

A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis

21 January 2018

1 reference

Comparison of IVIg and PLEX in patients with myasthenia gravis.

21 January 2018

1 reference

Comparative analysis of therapeutic options used for myasthenia gravis

21 January 2018

1 reference

A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group

21 January 2018

1 reference

Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide

21 January 2018

1 reference

A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis

21 January 2018

1 reference

An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.

21 January 2018

1 reference

A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis

21 January 2018

1 reference

Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients

21 January 2018

1 reference

Two-year treatment with cyclosporine microemulsion for responder myasthenia gravis patients

21 January 2018

1 reference

Successful treatment of myasthenia gravis with tacrolimus

21 January 2018

1 reference

Tacrolimus (FK506) in the treatment of prednisone-resistant myasthenia gravis. Preliminary results of 20 cases

21 January 2018

1 reference

21 January 2018

1 reference

Rituximab: clinical development and future directions

21 January 2018

1 reference

Requirement for safety monitoring for approved multiple sclerosis therapies: an overview

21 January 2018

1 reference

Monoclonal antibodies in treatment of multiple sclerosis

21 January 2018

1 reference

Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study.

21 January 2018

1 reference

Rituximab for myasthenia gravis: three case reports and review of the literature

21 January 2018

1 reference

Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review

21 January 2018

1 reference

The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.

21 January 2018

1 reference

Rituximab in the management of refractory myasthenia gravis

21 January 2018

1 reference

Rituximab for severe myasthenia gravis--experience from five patients

21 January 2018

1 reference

Response to therapy in myasthenia gravis with anti-MuSK antibodies

21 January 2018

1 reference

PML and rheumatology: the contribution of disease and drugs

21 January 2018

1 reference

Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy in autoimmune diseases

21 January 2018

1 reference

Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis.

21 January 2018

1 reference

Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein.

21 January 2018

1 reference

Etanercept treatment in corticosteroid-dependent myasthenia gravis

21 January 2018

1 reference

Myasthenia gravis associated with etanercept therapy

21 January 2018

1 reference

Functional defect in regulatory T cells in myasthenia gravis

21 January 2018

1 reference

Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells

21 January 2018

1 reference

Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis

21 January 2018

1 reference

B-cell-activating factor and autoimmune myasthenia gravis

21 January 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927901

Early effect of tacrolimus in improving excitation-contraction coupling in myasthenia gravis

21 November 2018

1 reference

12 December 2020

A clinical therapeutic trial of cyclosporine in myasthenia gravis

1 reference

12 December 2020

Improvement with rituximab in a patient with both rheumatoid arthritis and myasthenia gravis

1 reference

12 December 2020

Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis

1 reference

12 December 2020

Paraneoplastic myasthenia gravis: detection of anti-MGT30 (titin) antibodies predicts thymic epithelial tumor

1 reference

12 December 2020

A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis

1 reference

12 December 2020

FK506 prevents induction of rat experimental autoimmune myasthenia gravis

1 reference

12 December 2020

Increase in incidence of elderly-onset patients with myasthenia gravis in Nagano Prefecture, Japan

1 reference

12 December 2020

High-dose intravenous immunoglobulin for the treatment of MuSK antibody-positive seronegative myasthenia gravis

1 reference

12 December 2020

Post-thymectomy combined treatment of prednisone and tacrolimus versus prednisone alone for consolidation of complete stable remission in patients with myasthenia gravis: a non-randomized, non-controlled study

1 reference

12 December 2020

The role of B cell-activating factor in autoimmune myasthenia gravis

1 reference

12 December 2020

Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies

1 reference

12 December 2020

Rituximab in the treatment of MuSK antibody-positive myasthenia gravis

1 reference

12 December 2020

Further developments with antisense treatment for myasthenia gravis

1 reference

12 December 2020

Long-term cyclosporine treatment in a group of severe myasthenia gravis patients

1 reference

12 December 2020

Identifiers

DOI

10.1111/CEI.12217

1 reference

1 August 2017

0 references

1 reference